Squarepoint’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $79.7M | Sell |
3,310,002
-2,123,649
| -39% | -$55.6M | 0.09% | 223 |
|
|
2026
Q1 | $153M | Sell |
5,433,651
-4,249,615
| -44% | -$113M | 0.18% | 86 |
|
|
2025
Q4 | $241M | Sell |
9,683,266
-596,907
| -6% | -$15.1M | 0.26% | 60 |
|
|
2025
Q3 | $262M | Buy |
10,280,173
+1,125,612
| +12% | +$27.8M | 0.26% | 58 |
|
|
2025
Q2 | $222M | Buy |
9,154,561
+2,033,462
| +29% | +$47.4M | 0.23% | 70 |
|
|
2025
Q1 | $180M | Buy |
7,121,099
+4,403,532
| +162% | +$115M | 0.22% | 70 |
|
|
2024
Q4 | $72.1M | Buy |
2,717,567
+2,082,399
| +328% | +$56.5M | 0.07% | 270 |
|
|
2024
Q3 | $18.4M | Sell |
635,168
-111,960
| -15% | -$3.27M | 0.03% | 631 |
|
|
2024
Q2 | $20.9M | Sell |
747,128
-835,554
| -53% | -$23M | 0.03% | 563 |
|
|
2024
Q1 | $43.9M | Sell |
1,582,682
-1,748,539
| -52% | -$48.5M | 0.08% | 300 |
|
|
2023
Q4 | $95.9M | Buy |
3,331,221
+1,523,104
| +84% | +$46M | 0.18% | 96 |
|
|
2023
Q3 | $60M | Buy |
1,808,117
+352,433
| +24% | +$12.5M | 0.15% | 125 |
|
|
2023
Q2 | $53.4M | Buy |
1,455,684
+268,818
| +23% | +$10.5M | 0.16% | 122 |
|
|
2023
Q1 | $48.4M | Buy |
1,186,866
+902,536
| +317% | +$39M | 0.2% | 93 |
|
|
2022
Q4 | $14.6M | Sell |
284,330
-853,957
| -75% | -$40.9M | 0.06% | 361 |
|
|
2022
Q3 | $49.8M | Buy |
1,138,287
+851,577
| +297% | +$41.4M | 0.25% | 66 |
|
|
2022
Q2 | $15M | Sell |
286,710
-130,206
| -31% | -$6.64M | 0.08% | 272 |
|
|
2022
Q1 | $21.6M | Sell |
416,916
-278,183
| -40% | -$14.4M | 0.09% | 220 |
|
|
2021
Q4 | $41M | Sell |
695,099
-505,694
| -42% | -$25.1M | 0.11% | 151 |
|
|
2021
Q3 | $51.6M | Buy |
1,200,793
+808,951
| +206% | +$35.8M | 0.15% | 134 |
|
|
2021
Q2 | $15.3M | Sell |
391,842
-315,241
| -45% | -$12.3M | 0.06% | 309 |
|
|
2021
Q1 | $25.6M | Buy |
707,083
+16,419
| +2% | +$583K | 0.15% | 135 |
|
|
2020
Q4 | $25.4M | Buy |
690,664
+424,879
| +160% | +$15.6M | 0.19% | 89 |
|
|
2020
Q3 | $9.26M | Sell |
265,785
-1,168,490
| -81% | -$41M | 0.12% | 195 |
|
|
2020
Q2 | $44.5M | Buy |
1,434,275
+1,112,521
| +346% | +$37.8M | 0.72% | 3 |
|
|
2020
Q1 | $9.96M | Sell |
321,754
-1,532,098
| -83% | -$52.2M | 0.25% | 81 |
|
|
2019
Q4 | $68.9M | Buy |
1,853,852
+522,322
| +39% | +$18.6M | 0.41% | 17 |
|
|
2019
Q3 | $45.4M | Buy |
1,331,530
+1,240,572
| +1,364% | +$45.1M | 0.41% | 31 |
|
|
2019
Q2 | $3.74M | Sell |
90,958
-30,825
| -25% | -$1.22M | 0.04% | 554 |
|
|
2019
Q1 | $4.91M | Buy |
+121,783
| New | +$4.88M | 0.05% | 445 |
|
|
2018
Q4 | – | Sell |
-17,610
| Closed | -$736K | – | 2174 |
|
|
2018
Q3 | $736K | Sell |
17,610
-164,297
| -90% | -$6.32M | 0.01% | 1133 |
|
|
2018
Q2 | $6.26M | Sell |
181,907
-538,716
| -75% | -$18.4M | 0.08% | 347 |
|
|
2018
Q1 | $24.3M | Sell |
720,623
-116,541
| -14% | -$4.01M | 0.39% | 53 |
|
|
2017
Q4 | $28.8M | Buy |
837,164
+694,769
| +488% | +$23.7M | 0.5% | 26 |
|
|
2017
Q3 | $4.82M | Buy |
+142,395
| New | +$4.58M | 0.09% | 279 |
|
|
2017
Q2 | – | Sell |
-180,733
| Closed | -$5.87M | – | 1737 |
|
|
2017
Q1 | $5.87M | Sell |
180,733
-71,533
| -28% | -$2.26M | 0.16% | 147 |
|
|
2016
Q4 | $7.77M | Buy |
252,266
+90,803
| +56% | +$2.77M | 0.32% | 61 |
|
|
2016
Q3 | $5.19M | Sell |
161,463
-87,389
| -35% | -$2.92M | 0.34% | 61 |
|
|
2016
Q2 | $8.31M | Buy |
248,852
+67,186
| +37% | +$2.14M | 0.52% | 22 |
|
|
2016
Q1 | $5.11M | Buy |
181,666
+9,775
| +6% | +$279K | 0.4% | 36 |
|
|
2015
Q4 | $5.26M | Buy |
+171,891
| New | +$5.41M | 0.58% | 10 |
|
|
2015
Q2 | – | Sell |
-65,594
| Closed | -$2.17M | – | 571 |
|
|
2015
Q1 | $2.17M | Buy |
+65,594
| New | +$2.09M | 0.76% | 19 |
|
Other funds holding PFE
Squarepoint's PFE Position: Q2 2026 in Review
Squarepoint reduced its Pfizer (PFE) stake by 39% in Q2 2026, selling an estimated $55.6M and leaving 3,310,002 shares worth $79.7M. The position accounts for 0.09% of the portfolio, ranked #223.
Squarepoint first reported a position in PFE in Q1 2015 and has held it in 42 quarters since. The position peaked at $262M in Q3 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Squarepoint held 3,310,002 shares of Pfizer worth $79.7M as of Q2 2026.
- Squarepoint sold 2,123,649 Pfizer shares in Q2 2026, an estimated $55.6M.
- Pfizer made up 0.09% of Squarepoint's portfolio in Q2 2026, its #223 holding.
- Squarepoint first reported a position in Pfizer in Q1 2015 and has held it in 42 quarters since.
- Squarepoint's Pfizer position peaked at $262M in Q3 2025.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.